Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Net Margin (2016 - 2025)

Historic Net Margin for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to 1.22%.

  • International Stem Cell's Net Margin rose 69600.0% to 1.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.58%, marking a year-over-year increase of 70400.0%. This contributed to the annual value of 2.34% for FY2024, which is 79500.0% up from last year.
  • Per International Stem Cell's latest filing, its Net Margin stood at 1.22% for Q3 2025, which was up 69600.0% from 2.74% recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's Net Margin ranged from a high of 14.07% in Q2 2023 and a low of 36.13% during Q1 2021
  • Its 5-year average for Net Margin is 9.14%, with a median of 5.74% in 2024.
  • As far as peak fluctuations go, International Stem Cell's Net Margin skyrocketed by 356800bps in 2022, and later plummeted by -254000bps in 2023.
  • Quarter analysis of 5 years shows International Stem Cell's Net Margin stood at 19.75% in 2021, then skyrocketed by 106bps to 1.15% in 2022, then tumbled by -2204bps to 24.25% in 2023, then surged by 102bps to 0.49% in 2024, then soared by 150bps to 1.22% in 2025.
  • Its Net Margin stands at 1.22% for Q3 2025, versus 2.74% for Q2 2025 and 12.02% for Q1 2025.